Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endolymphatic Hydrops Clear all
Active, not recruiting Phase 3 Interventional

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

NCT06859788
View directory record Official record
Conditions
Meniere's Disease, Ménière's Disease
Interventions
Ebselen
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Boynton Beach, Florida • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Infrasound Exposure on Measures of Endolymphatic Hydrops

NCT03132961
View directory record Official record
Conditions
Vestibular Abnormality, Endolymphatic Hydrops
Interventions
Infrasound exposure
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 22, 2026, 1:44 AM EDT
Terminated Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02717442
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

NCT01267994
View directory record Official record
Conditions
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
Interventions
Anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
13 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

OTO-104 for the Treatment of Meniere's Disease

NCT01412177
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Diego, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 22, 2026, 1:44 AM EDT
Not listed Phase 2 Interventional

Lamotrigine and Bupropion for Meniere's Disease

NCT05420350
View directory record Official record
Conditions
Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine and Bupropion, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 22, 2026, 1:44 AM EDT
Active, not recruiting Phase 4 Interventional

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

NCT04815187
View directory record Official record
Conditions
Meniere Disease, Allergic Rhinitis, Vertigo
Interventions
Montelukast, Placebo
Drug
Lead sponsor
House Ear Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT03664674
View directory record Official record
Conditions
Meniere Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Fresno, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 22, 2026, 1:44 AM EDT
Not listed Early Phase 1 Interventional

Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection

NCT04794842
View directory record Official record
Conditions
Intratympanic Steroid Injection, Idiopathic Sudden Sensorineural Hearing Loss, Meniere Disease
Interventions
Tetracaine 5% drops, Phenol 90% concentration
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 1:44 AM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

NCT02603081
View directory record Official record
Conditions
Meniere's Disease
Interventions
SPI-1005
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Withdrawn Not applicable Interventional

Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops

NCT01661777
View directory record Official record
Conditions
Eustachian Tube Dysfunction, Endolymphatic Hydrops
Interventions
Nasal steroid, Myringotomy tube placement, Diuretic, Antihistamine, Low salt diet
Drug · Procedure · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 22, 2026, 1:44 AM EDT
Recruiting Phase 4 Interventional

Treatment of Meniere's Disease With Migraine Medications

NCT05582837
View directory record Official record
Conditions
Ménière
Interventions
nortriptyline + topiramate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Terminated Phase 3 Interventional Results available

A 6-Month Extension Study of OTO-104 in Meniere's Disease

NCT02768662
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

SPI-1005 for the Treatment of Meniere's Disease

NCT04677972
View directory record Official record
Conditions
Meniere Disease, Ménière
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02612337
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

NCT01950312
View directory record Official record
Conditions
Autoimmune Inner Ear Disease
Interventions
gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand

NCT05960786
View directory record Official record
Conditions
Vertigo, BPPV, Meniere Disease, Labrynthitis, Vestibular Disorder, Vestibular Migraine, Benign Paroxysmal Positional Vertigo, Ménière's Vertigo, Migraine Associated Vertigo, Uncompensated Unilateral Vestibulopathy
Interventions
Otoband Experimental, Otoband Sham
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

NCT04869020
View directory record Official record
Conditions
Vertigo
Interventions
Otoband, Sham A, Sham B
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 1:44 AM EDT
Withdrawn Not applicable Interventional

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

NCT02371798
View directory record Official record
Conditions
Meniere Disease
Interventions
Gadopentetate dimeglumine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 22, 2026, 1:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets

NCT04806282
View directory record Official record
Conditions
Meniere's Disease, Enlarged Vestibular Aqueduct Syndrome, Autoimmune Inner Ear Disease
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Not applicable Interventional Results available

Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach

NCT02309099
View directory record Official record
Conditions
Unilateral Acoustic Neuroma, Meniere's Disease
Interventions
Cochlear Implant
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 22, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

OTO-104 for Meniere's Disease

NCT01084525
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 22, 2026, 1:44 AM EDT
Active, not recruiting Not applicable Interventional

CI Following VS Removal or Labyrinthectomy

NCT03795675
View directory record Official record
Conditions
Vestibular Schwannoma, Meniere Disease
Interventions
Cochlear Implant
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 1:44 AM EDT